ReviewInternational journal of molecular medicine2026
CLDN7: Epithelial gatekeeper from physiology to pathology‑roles in cancer and epithelial‑related diseases (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudin‑7 (CLDN7) is a key component of epithelial tight junctions. It plays a vital role in maintaining cell polarity, barrier integrity and paracellular transport. Abnormal CLDN7 expression is closely related to the onset and progression of various diseases. It is especially markedly associated with the growth and metastasis of multiple cancers. Additionally, dysregulated CLDN7 expression contributes to the progression of intestinal, skin and respiratory system diseases. The present review summarized the structure, expression, physiological functions, stability and regulatory mechanisms of CLDN7, emphasizing its role in tumors. The expression patterns, regulatory mechanisms, effect on malignant phenotypes and clinical significance of CLDN7 were also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.